Pharmacelsus GmbH


Pharmacelsus, Germany´s market-leading early stage CRO, plans, organizes and realizes customized preclinical studies for more than 20 years. Our assays meet national and international regulatory demands while using our unique consultative approach to serve more than 120+ satisfied customers who rely on our expertise, experience and passion for science.

The Pharmacelsus portfolio covers the complete drug discovery and development testing program for small molecules and peptides in vitro, in vivo, ex vivo as well as G(C)LP and non-GLP bioanalysis. Structural, physicochemical and functional characterization of Biopharmaceuticals (e.g. Antibodies, ADCs, etc.) complements our comprehensive portfolio.

More about Pharmacelsus
  • News

    ElexoPharm Receives € 2.1 Million EUROSTARS Grant

    A EUROSTARS grant of €2.1 million has been awarded to a transnational consortium consisting of Khondrion BV ( Nijmegen), Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen), Pharmacelsus GmbH (Saarbruecken) and ElexoPharm GmbH (Saarbruecken). This grant, which for the German partne ... more

    New Hope in Fight Against the Flu

    Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project “FLUCURE” supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also jo ... more

    Pharmacelsus’ GLP implementation exemplary for European CROs

    Pharmacelsus obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP implementation ... more